<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_Trieste_project_overview"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu noprint"><UL><LI class="selected"><A href="/Team:Trieste/project/overview">Page               </A></LI><LI class="new"><A href="/wiki/index.php?title=Talk:Team:Trieste/project/overview&amp;action=edit&amp;redlink=1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:Trieste/project/overview&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:Trieste/project/overview&amp;action=history">History               </A></LI><LI style="color:#808080;cursor:default">teams</LI></UL></DIV><DIV class="right-menu noprint" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:Trieste/project/overview" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls" class="noprint"><FORM action="/Special:Search" id="searchform"> </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:Trieste/project/overview</H1><DIV id="bodyContent"><H3 id="siteSub" class="noprint">From 2012.igem.org</H3><DIV id="head"><TITLE>Team Trieste iGEM 2012</TITLE></DIV><DIV id="body"><DIV id="container"><DIV id="header"><DIV id="payoff">The Jolly JoCare<DIV>a safe probiotic platform for protein expression</DIV></DIV><UL id="navigation"><LI><A href="https://2012.igem.org/Team:Trieste">HOME</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/team">TEAM</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/team">Team</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/City&amp;Lab">City&amp;Lab</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/Team Gal">Team Gallery</A></LI></UL><LI><A href="https://2012.igem.org/Team:Trieste/project">PROJECT</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/project">Abstract</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/project/overview">Project Overview</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/project/applications">Applications</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/project/modeling">Modeling</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/project/mainres">Main Results</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/data">DATA</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/parts">PARTS</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/notebook">DIARY</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/notebook">Notebook</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/protocols">Protocols</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/safety">SAFETY</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/safety">Safety</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/survey">Safety Survey</A></LI><LI><A href="http://www.icgeb.org/~bsafesrv/" target="_blank">ICGEB Safety Unit</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/outreach">OUTREACH</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/outreach">Human Practice</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/outreach/press">Press</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/extra">EXTRA</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/extra">Attributions</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/extra/ach">Achievements</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/extra/aks">Acknowledgement</A></LI></DIV><DIV id="content"><H1 id="h1_lf" class="main_tit"><DIV>Project Overview</DIV></H1><H1 id="h1_rt" class="main_tit"><DIV>More</DIV></H1><DIV id="box_main"><DIV class="box_contenuti"><H1>Background</H1><P class="fancy">
					The human intestinal microflora is considered an essential “organ”
					which plays an important role in human health.	This complex ecosystem
					is composed of approximately 500 anaerobic and aerobic bacteria species,
					most of them localized in large intestine.
				</P><P class="fancy">
					Many studies on animals
					bred under germ-free conditions have shown that microflora has specific
					functions:
					<UL class="fancy"><LI>
							Metabolic: fermentation of non-digestible dietary residue and
							endogenous mucus, salvage of energy as short-chain fatty acids,
							production of vitamin K, absorption of ions;
					    </LI><LI>
							Trophic: control of epithelial cell proliferation and differentiation;
							development and homoeostasis of the immune system;
					    </LI><LI>Protective: protection against pathogens. </LI></UL></P><P class="fancy">
					A disruption or an alteration of human gut microflora equilibrium leads
					to severe auto-immune diseases, types of colon cancer and non-allergic
					food hypersensitivities; therefore, it is very important to keep its
					integrity.  In fact already a century ago, the first probiotics have
					been commercialized. Probiotics are bacteria species (normally present
					in human gut) that are administered as food components or supplements.
					Nowadays, with the emerging research field of synthetic biology the
					potential applications of probiotics could further increase. In addition,
					the introduction of novel functions to this “organ” via probiotics
					could lead the way to new therapeutics in order to cure or prevent many
					pathological conditions.
			    </P><H1>Project overview</H1><P class="fancy">
					We engineered an indigenous strain from the gut microflora in order to
					create a safe, controllable and versatile molecular platform, which can
					be used for production of a wide range of molecules.  For this purpose
					we used the <I>Escherichia coli</I> strain Nissle 1917 (commercialized as
					Mutaflor) as the host organism for our platform. This particular strain
					has been used as a probiotic for decades and its beneficial effects
					on human health are well documented. We introduced into the strain a
					gene guard system based on an inducible cumate gene guard switch and we
					trasformed it with a particularly designed plasmid for protein expression.
				</P><P class="fancy">
					The gene guard system is divided in two parts:
					<UL class="fancy"><LI><STRONG>the killing mechanism</STRONG></LI><LI><STRONG>the regulating pattern</STRONG></LI></UL></P><P class="fancy">
				The killing mechanism is placed on the  same plasmid used for protein
				expression. It consists of two different proteins, T4 Holin<SUP><A href="#sup1">[1]</A></SUP> and
				Cathelicidin LL-37<SUP><A href="#sup2">[2]</A></SUP>,
				both toxic for prokaryotic cells. These antimicrobial
				proteins are both regulated by a cumate responsive promoter (T5 promoter
				Cumate Operator<SUP><A href="#sup3">[3]</A><A href="sup4">[4]</A></SUP>)
				placed upstream the structural genes. Holin is the
				biobrick BBa_K112000 designed by group iGEM08 UC Berkeley. This protein
				comes from bacteriophage T4; it is a small membrane protein which
				depolarizes and permeabilizes the membrane allowing the secretion of
				Cathelicidin LL-37 to the periplasm. Cathelicidin LL-37 is an antimicrobial
				peptide produced by human macrophages. It has an amphypathic structure
				that allows it to associate with bacterial membrane and form pores which
				lead to cell lysis; its presence in the periplasm is pivotal for its
				killing effect. As an alternative killing mechanism the complex T4 Holin +
				Cathelicidin LL-37 can be replaced with TSE 2 toxin, a standard biobrick
				BBa_K314200 designed and characterized by Group iGEM10 Washington. TSE
				2 arrests the bacterial growth.
				</P><P class="fancy">
				The cumate-responsive regulator CymR<SUP><A href="#sup3">[3]</A><A href="sup4">[4]</A></SUP>,
				which regulates the expression of the T4 Holin and Cathelicidin LL-37,
				will be introduced into the bacterial chromosome by recombination using
				the UPO-Sevilla miniTn7 Biobrick together with the helper plasmid pTNS2
				which codes for the Tn7 transposase.  The regulator cassette consists
				of a constitutive promoter (J23100) and the cymR gene, put in tandem
				in order to increase the quantity of the repressor  to	tightly control
				toxin expression.
			    </P><H2>No Cumate Expression Mode:</H2>
				CymR is continuously produced. It binds the cumate responsive promoter (T5 Cumate Operator) and inhibits the expression of T4 Holin and Cathelicidin LL-37.<STRONG>Bacteria live!</STRONG><H2>Cumate-Induction Kill Mode:</H2>
				Cumate enters by diffusion into bacteria, binds and inactivates the
				repressor. The cumate responsive promoter (T5 Cumate Operator) is
				derepressed and the expression of T4 Holin and Cathelicidin LL-37
				is turned on. T4 Holin interacts with the cytoplasmatic membrane,
				permeabilizes it allowing the secretion of Cathelicidin LL-37 into the
				periplasmic space. Cathelicidin LL-37 binds the outermembrane and forms
				pores, which leads to cell lysis.<STRONG>Bacteria die!</STRONG><H2>Plasmid Transfer:</H2><OL class="fancy"><LI>
								The plasmid transfers from the <I>E. coli</I> Nissle into other bacteria
								via horizontal transfer. The receiving bacteria do not produce
								the CymR repressor, so the cumate responsive promoter (T5 Cumate
								Operator) is derepressed and the T4 Holin and Cathelicidin
								LL-37 expression is activated.<STRONG>Receiving bacteria die!</STRONG></LI><LI><I>E. coli</I> Nissle looses the plasmid. It continues to produce the
								CymR repressor, which does not appear to be toxic for prokaryotic
								cells.<STRONG>Bacteria live and are harmless!</STRONG></LI></OL><DIV class="footnotes"><H3>References</H3><P id="sup1">
								[1]: <STRONG>Genetic analysis od the T4 holin: timing and topology</STRONG>
								Erlan Ramanculov, Ry Young
								Gene, March 2001, Volume 256, Issues 1-2, Pages 25-36 doi:10.1016-S0378-1119(01)00365-1
						</P><P id="sup2">
							[2]: <STRONG>LL-37, the only human member of the cathelicidin family of antimicrobial peptides</STRONG>
							Ulrich H.N. Dürr, U.S. Suadheendra, Ayyalusamy Ramamoorthy 
							Biochimica et Biophysica Acta, September 2006, Volume 1758, Issue 9, Pages 1406-1425 doi:10.1016/j.bbamem.2006.003.030
						</P><P id="sup3">
							[3]: <STRONG>The cumate gene-switch: a system for regulated expression in mammalian cells</STRONG>
							Alaka Mullick, Yan Xu, René Warren, Maria Koutroumanis, Claire Guilbault, Sophie Broussau, Félix Malenfant, Lucie Bourget, Linda Lamoureux, Rita Lo, Antoine W Caron, Amelie Pilotte and Bernard Massie
							BMC Biotechnology, 2006, 6:43   doi:10.1186/1472-6750-6-43
						</P><P id="sup4">
							[4]: <STRONG>Novel, Versatile, and Tightly Regulated Expression System for Escherichia coli Strains</STRONG>
							Young J. Choi, Lyne Morel, Teffanie Le François Denis Bourque, Lucie Bourget, Denis Groleau, Bernard Massie and Carlos B. Míguez
							Applied and Environmental Microbiology, Aug. 2010, p. 5058–5066 Vol.76   doi:10.1128/AEM.00413-10
						</P></DIV></DIV></DIV><DIV id="box_right"><UL id="sub_menu"><LI><A href="https://2012.igem.org/Team:Trieste/project">Abstract</A></LI><LI class="select"><A href="https://2012.igem.org/Team:Trieste/project/overview">Project Overview</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/project/applications">Applications</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/project/modeling">Modeling</A></LI><LI><A href="https://2012.igem.org/Team:Trieste/project/mainres">Main Results</A></LI></UL><DIV class="box_contacts"><H2>Contact us</H2><P>For other information, write to:</P><A href="mailto:igem2012@gmail.com" class="btn">igem2012@gmail.com</A><DIV class="social">
                    Follow us also:
			</DIV></DIV></DIV></DIV><DIV id="footer"><DIV id="box_footer">iGEM 2012 - For info: <A href="mailto:igem2012@gmail.com">igem2012@gmail.com</A></DIV></DIV></DIV></DIV><DIV class="printfooter">
Retrieved from &quot;<A href="http://2012.igem.org/Team:Trieste/project/overview">http://2012.igem.org/Team:Trieste/project/overview</A>&quot;</DIV></DIV></DIV><DIV id="footer-box" class="noprint"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:Trieste/project/overview" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:Trieste/project/overview" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:Trieste/project/overview&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:Trieste/project/overview&amp;oldid=230236" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2012.igem.org:Privacy_policy" title="2012.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2012.igem.org:General_disclaimer" title="2012.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></DIV></BODY></HTML>